These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27717163)

  • 1. Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces.
    Yu T; Chisholm J; Choi WJ; Anonuevo A; Pulicare S; Zhong W; Chen M; Fridley C; Lai SK; Ensign LM; Suk JS; Hanes J
    Adv Healthc Mater; 2016 Nov; 5(21):2745-2750. PubMed ID: 27717163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions.
    Popov A
    J Ocul Pharmacol Ther; 2020; 36(6):366-375. PubMed ID: 32667250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
    Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L
    Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
    Chavhan SS; Petkar KC; Sawant KK
    Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylation for enhancing nanoparticle diffusion in mucus.
    Huckaby JT; Lai SK
    Adv Drug Deliv Rev; 2018 Jan; 124():125-139. PubMed ID: 28882703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanosuspensions: a promising drug delivery strategy.
    Patravale VB; Date AA; Kulkarni RM
    J Pharm Pharmacol; 2004 Jul; 56(7):827-40. PubMed ID: 15233860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocrystal technology in the delivery of poorly soluble drugs: an overview.
    Nagarwal RC; Kumar R; Dhanawat M; Das N; Pandit JK
    Curr Drug Deliv; 2011 Jul; 8(4):398-406. PubMed ID: 21453258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
    Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
    Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies.
    Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y
    Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs.
    Gao L; Liu G; Ma J; Wang X; Zhou L; Li X; Wang F
    Pharm Res; 2013 Feb; 30(2):307-24. PubMed ID: 23073665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
    Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
    Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarriers for oral drug delivery.
    Zhang L; Wang S; Zhang M; Sun J
    J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation, characterization, and fate of inhaled drug nanoparticles.
    Zhang J; Wu L; Chan HK; Watanabe W
    Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of injectable drug nanocrystals.
    Fuhrmann K; Gauthier MA; Leroux JC
    Mol Pharm; 2014 Jun; 11(6):1762-71. PubMed ID: 24766270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocrystal for ocular drug delivery: hope or hype.
    Sharma OP; Patel V; Mehta T
    Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucus as a barrier to lipophilic drugs.
    Sigurdsson HH; Kirch J; Lehr CM
    Int J Pharm; 2013 Aug; 453(1):56-64. PubMed ID: 23727593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
    Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
    Constantinides PP; Chaubal MV; Shorr R
    Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.